Abstract
| 245 -0.6), WOCF (-1.1), PMI (-0.6), modified BOCF (-0.8), and OC for patients who completed treatment (-1.0). The most frequently reported treatment-emergent adverse events were nausea, dizziness, and somnolence in the OL phase, and nausea, anxiety, and diarrhea in the tapentadol ER group in the DB phase. conclusion: Significant improvement in the primary endpoint was demonstrated with all imputation methods used, indicating that the efficacy of tapentadol ER was robust in this study of patients with moderate to severe chronic pain related to DPN. Complications nerve Conflict of interest Employee: ME, DYS, AO, and JH are employees of Johnson & Johnson. AS is an employee of Grunenthal GmbH.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
